“Data presented today at SITC in the GARNET study were positive, and better than data presented in this setting earlier this year, and compared favorably to the reference data in this setting. Data from CITRINO for TSR-033 demonstrated that TSR-033 monotherapy was well tolerated across multiple dose levels. Preclinical experiments for TSR-022 indicated the combination of PD-1 and TIM3 blockade induces tumor regressions, and the triple blockade of LAG-3 resulted in highly effective reversal of T cell exhaustion in a murine model. Based on the development stage and timing of TSR-022, we do not have any revenue expectations in our model at this time for this compound through 2022, but believe these compounds offer upside for Tesaro.”
According to TipRanks.com, Cann is a 4-star analyst with an average return of 5.4% and a 41.8% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.
Tesaro has an analyst consensus of Moderate Buy, with a price target consensus of $52.50, a 70.8% upside from current levels. In a report issued on November 2, Cantor Fitzgerald also maintained a Buy rating on the stock with a $68 price target.
The company has a one-year high of $92.71 and a one-year low of $25.62. Currently, Tesaro has an average volume of 1.66M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib.